

Michael Caruana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5000071/publications.pdf>

Version: 2024-02-01

28
papers

2,007
citations

430442

18
h-index

476904

29
g-index

29
all docs

29
docs citations

29
times ranked

2249
citing authors

#	ARTICLE	IF	CITATIONS
1	National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. <i>BMJ, The</i> , 2022, 376, e068582.	3.0	16
2	Trends in colon and rectal cancer mortality in Australia from 1972 to 2015 and associated projections to 2040. <i>Scientific Reports</i> , 2022, 12, 3994.	1.6	5
3	Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening. <i>Lung Cancer</i> , 2022, 169, 47-54.	0.9	3
4	Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study. <i>Lancet Public Health, The</i> , 2022, 7, e537-e548.	4.7	38
5	The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. <i>Genetics in Medicine</i> , 2022, 24, 1831-1846.	1.1	6
6	Prevalence of skin examination behaviours among Australians over time. <i>Cancer Epidemiology</i> , 2021, 70, 101874.	0.8	11
7	The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. <i>Medical Journal of Australia</i> , 2020, 212, 72-81.	0.8	22
8	Pathways to a cancer-free future: a protocol for modelled evaluations to minimise the future burden of colorectal cancer in Australia. <i>BMJ Open</i> , 2020, 10, e036475.	0.8	1
9	Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials. <i>Medical Decision Making</i> , 2020, 40, 815-829.	1.2	14
10	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 575-590.	6.3	421
11	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 591-603.	6.3	321
12	Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?. <i>Lung Cancer</i> , 2019, 130, 208-215.	0.9	16
13	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. <i>Lancet Oncology, The</i> , 2019, 20, 394-407.	5.1	279
14	Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	20
15	Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. <i>International Journal of Cancer</i> , 2018, 143, 269-282.	2.3	28
16	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. <i>BMJ Open</i> , 2018, 8, e016700.	0.8	20
17	Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study. <i>Scientific Reports</i> , 2018, 8, 4261.	1.6	12
18	Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1450-1461.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Lung cancer mortality in Australia: Projected outcomes to 2040. Lung Cancer, 2018, 125, 68-76.	0.9	21
20	Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health, The, 2017, 2, e96-e107.	4.7	124
21	Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO ₂₀₁₂ risk prediction tool. International Journal of Cancer, 2017, 141, 242-253.	2.3	73
22	How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country. International Journal of Cancer, 2017, 141, 2410-2422.	2.3	25
23	Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lancet Public Health, The, 2017, 2, e331-e340.	4.7	114
24	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Medicine, 2017, 14, e1002388.	3.9	67
25	Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health, The, 2016, 1, e66-e75.	4.7	37
26	A (rough) pathwise approach to a class of non-linear stochastic partial differential equations. Annales De L'Institut Henri Poincare (C) Analyse Non Lineaire, 2011, 28, 27-46.	0.7	52
27	Peano's theorem for rough differential equations in infinite-dimensional Banach spaces. Proceedings of the London Mathematical Society, 2010, 100, 177-215.	0.6	2
28	Partial differential equations driven by rough paths. Journal of Differential Equations, 2009, 247, 140-173.	1.1	39